CLINICAL TRIALS PROFILE FOR CIMZIA
✉ Email this page to a colleague
All Clinical Trials for CIMZIA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00245765 ↗ | Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy | Completed | UCB Pharma | Phase 2 | 2005-10-01 | A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up. |
| NCT00329303 ↗ | Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis | Completed | UCB Pharma | Phase 2 | 2006-04-01 | The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study. |
| NCT00580840 ↗ | Dosing Flexibility Study in Patients With Rheumatoid Arthritis | Completed | UCB Pharma | Phase 4 | 2007-12-01 | During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16. |
| NCT00717236 ↗ | Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis | Completed | UCB Pharma | Phase 3 | 2008-07-01 | This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis. |
| NCT00753454 ↗ | Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA) | Completed | UCB Pharma | Phase 3 | 2008-09-01 | The purpose of this study is to continue to assess the safety of certolizumab pegol in combination with methotrexate (MTX). |
| NCT00771667 ↗ | A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy | Completed | Centocor, Inc. | Phase 2 | 2008-12-01 | A medical research study in adult patients who have moderate to severe Crohn's disease designed to determine whether or not treatment with an experimental drug called ustekinumab (or CNTO1275) is safe or not and to determine if the treatment will reduce the symptoms of Crohn's disease. |
| NCT00844285 ↗ | SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry | Completed | UCB Pharma | 2009-01-01 | The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population. The SECURE Registry's target enrollment is 3045 patients and it's objective is to monitor patients for approximately 8 years. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CIMZIA
Condition Name
Clinical Trial Locations for CIMZIA
Trials by Country
Clinical Trial Progress for CIMZIA
Clinical Trial Phase
Clinical Trial Sponsors for CIMZIA
Sponsor Name
